Health Care
Biotech and Pharmaceuticals
featured
Martin Shkreli was convicted of three criminal counts but acquitted of five others. » Read More
By: Dan Mangan
Martin Shkreli was convicted of three criminal counts but acquitted of five others. He faces possible prison time. » Read More |
Drugmaker Hikma's US unit reportedly raised the price of a common diarrhea drug by more than 400 percent. » Read More |
Wall Street investor Jonathan Silverstein has spent a career finding and funding biotech firms working on cures for rare diseases. But after learning in February he has Parkinson’s Disease, the diagnosis set him and his wife on a path to create a different kind of startup, a foundation to work towards a cure. » Read More |
More
Jim Cramer made sense of the recent sell-off in the market and warned investors that the worst isn’t over.
Jim Cramer sat down with the founder of Allurion Technologies to hear about his privately-held biotech company's revolutionary obesity treatment.
The FDA approved Pfizer's rare blood cancer drug, Besponsa, with a boxed warning.
U.S. Representatives Elijah Cummings and Peter Welch sent the letters to seven drugmakers.
JPMorgan's research team shared its top biotech stock picks coming out of the second-quarter earnings season.
Mylan said 10 months ago it reached a deal resolving claims it misclassified the EpiPen as a generic.
Jim Cramer sat down with Joe Papa, the new CEO of the controversial Valeant Pharmaceuticals, to catch up on the drugmaker's turnaround.
Jim Cramer dished out his shopping list of stocks ripe for the picking, despite turmoil in Washington.
Jim Cramer dished out his shopping list of stocks ripe for the picking, despite turmoil in Washington.
Jim Cramer sat down with Joe Papa, the new CEO of the controversial Valeant Pharmaceuticals, to catch up on the drugmaker's turnaround.
Jim Cramer sat down with Joe Papa, the new CEO of the controversial Valeant Pharmaceuticals, to catch up on the drugmaker's turnaround.
The complaint also blasts Goldman for having few blacks in leadership positions.
Research analyst Terence Flynn added Biogen to Goldman Sachs' Americas Conviction List on optimism its Alzheimer's drug may be the first to successfully slow the progression of the disease.
Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.
The president may want to check his "facts" on Merck, which he accused of "taking jobs out of the U.S."
'I'm feeling great, doing great,' Shkreli says in an interview.
Contact Biotech and Pharma
-
CNBC NEWSLETTERS
Get the best of CNBC in your inbox
Get these newsletters delivered to your inbox, and more info about our products and service. Privacy Policy.▲Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals.
Bertha Coombs is a general assignment reporter for CNBC, covering financial markets and business news stories.
